NPPB and familial dilated cardiomyopathy: Additionally, female gender (HR: 0.66, 95% CI = 0.45–0.98, p = 0.04), increased LVEF (HR: 0.97, 95% CI = 0.59–0.99, p = 0.001) and use of beta-blocker therapy (HR: 0.79, 95% CI = 0.66–0.95, p = 0.01) were significant predictors for survival in patients with DCM, while advanced NYHA class (HR: 1.39, 95% CI = 1.03–1.87, p = 0.03) and BNP > 7897 pg/mL (HR: 1.27, 95% CI = 1.06–1.52, p = 0.01) were associated with cardiac death in DCM patients.